Gene therapy progress for HIV

Drug Discovery Today

Volumn 7, Issue 16, 2002, Pages 841-842

  Clayton, Julie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; COMPLEMENTARY RNA; GLYCOPROTEIN GP 120; GROWTH FACTOR; INTERLEUKIN 2;

ANTIGEN SPECIFICITY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; SHORT SURVEY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ARTICLE; PHASE 1 CLINICAL TRIAL;

CLINICAL TRIALS, PHASE I; GENE THERAPY; HIV INFECTIONS; HUMAN; HUMANS;

EID: 0037101895     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02418-2     Document Type: Short Survey

References (4)

1. Use of lentivirus vectors to engineer T cells for immunotherapy of HIV infection
2. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection
3. A Phase II randomized study of HIV-specific T-cell therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy
4. Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector